Richard Schilsky to Combined Modality Therapy
This is a "connection" page, showing publications Richard Schilsky has written about Combined Modality Therapy.
Connection Strength
0.193
-
Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol. 2010 Jun; 7(6):318-25.
Score: 0.070
-
A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. Ann Oncol. 2000 Apr; 11(4):415-20.
Score: 0.035
-
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019 05; 25(5):751-758.
Score: 0.033
-
Ovarian function following radiation and chemotherapy for cancer. Semin Oncol. 1989 Oct; 16(5):425-36.
Score: 0.017
-
Nonmalignant complications of therapy for Hodgkin's disease. Hematol Oncol Clin North Am. 1989 Jun; 3(2):331-43.
Score: 0.016
-
Adjuvant therapy for colorectal cancer. Curr Probl Surg. 1997 Aug; 34(8):601-76.
Score: 0.007
-
Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol. 1989 Jun; 7(6):761-8.
Score: 0.004
-
Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results. Otolaryngol Head Neck Surg. 1988 Apr; 98(4):295-8.
Score: 0.004
-
The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of malignant lymphomas. Cancer Invest. 1988; 6(4):427-37.
Score: 0.004
-
Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer. NCI Monogr. 1988; (6):353-6.
Score: 0.004